furosemide has been researched along with Disease Exacerbation in 41 studies
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.
furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Furosemide, either alone or in combination with captopril, is capable to prevent myocardial calcification, cardiac hypertrophy and hypertension, maintaining blood Ca(2+) and phosphate levels by slowing CRF." | 9.14 | Myocardial calcification and hypertension following chronic renal failure and ameliorative effects of furosemide and captopril. ( Kang, HS; Kim, JS; Kim, SJ; Kim, SZ; Lee, YU; Rahman, M, 2010) |
| " All dogs entered in the study received standard heart failure treatment (furosemide with or without digoxin)." | 9.08 | Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. The Long-Term Investigation of Veterinary Enalapril (LIVE) Study Group. ( Benitz, AM; Cifelli, S; Ericsson, GF; Ettinger, SJ; Hanson, PD; Jernigan, AD; Longhofer, SL; Trimboli, W, 1998) |
| "The use of the furosemide stress test (FST) as an acute kidney injury (AKI) severity marker has been described in several trials." | 9.05 | Furosemide stress test as a predictive marker of acute kidney injury progression or renal replacement therapy: a systemic review and meta-analysis. ( Chang, CH; Chen, JJ; Huang, YT; Kuo, G, 2020) |
| " This study aimed to compare the effect of torasemide and furosemide on long-term outcomes and New York Heart Association (NYHA) class change in patients with chronic heart failure (HF)." | 7.91 | Comparative Analysis of Long-Term Outcomes of Torasemide and Furosemide in Heart Failure Patients in Heart Failure Registries of the European Society of Cardiology. ( Balsam, P; Crespo-Leiro, MG; Drożdż, J; Filipiak, KJ; Grabowski, M; Kapłon-Cieślicka, A; Kowalik, R; Maggioni, AP; Marchel, M; Opolski, G; Ozierański, K; Peller, M; Tymińska, A; Wancerz, A, 2019) |
| "To validate the furosemide stress test (FST) for predicting the progression of acute kidney injury (AKI)." | 7.91 | The furosemide stress test for prediction of worsening acute kidney injury in critically ill patients: A multicenter, prospective, observational study. ( Bagshaw, SM; Chawla, LS; Koyner, JL; Liu, KD; McMahon, B; Rewa, OG; Shapiro, J; Smith, O; Trevino, SA; Wald, R; Wang, X, 2019) |
| "A long-acting loop diuretic, azosemide, has been shown to improve long-term prognosis in patients with heart failure compared with a short-acting loop diuretic, furosemide." | 7.91 | Patients With CONgestive Heart Failure Benefit From Long-Term Treatment Effects With Novel Treatment Using Azosemide Compared With Furosemide Derived From Existing Retrospective Study Data: CONTENTED. ( Abe, S; Arikawa, T; Inami, S; Inoue, T; Kanaya, T; Nishikawa, R; Saito, F; Sakuma, M; Toyoda, S; Watanabe, R, 2019) |
| "Furosemide shortened the time to left ventricular dysfunction (35." | 7.72 | Furosemide and the progression of left ventricular dysfunction in experimental heart failure. ( Haigney, MC; Hanlon, SU; McCurley, JM; Michalski, M; Wedam, EF; Wei, SK, 2004) |
| "Coexistent hepatocellular carcinoma (HCC) was the only significant predictive variable that attenuated the efficacy of TLV." | 5.46 | Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma. ( Goya, T; Kato, M; Kohjima, M; Kotoh, K; Masumoto, A; Miyazaki, M; Motomura, K; Senjyu, T; Tanaka, K; Yada, M, 2017) |
| "Furosemide, either alone or in combination with captopril, is capable to prevent myocardial calcification, cardiac hypertrophy and hypertension, maintaining blood Ca(2+) and phosphate levels by slowing CRF." | 5.14 | Myocardial calcification and hypertension following chronic renal failure and ameliorative effects of furosemide and captopril. ( Kang, HS; Kim, JS; Kim, SJ; Kim, SZ; Lee, YU; Rahman, M, 2010) |
| " All dogs entered in the study received standard heart failure treatment (furosemide with or without digoxin)." | 5.08 | Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. The Long-Term Investigation of Veterinary Enalapril (LIVE) Study Group. ( Benitz, AM; Cifelli, S; Ericsson, GF; Ettinger, SJ; Hanson, PD; Jernigan, AD; Longhofer, SL; Trimboli, W, 1998) |
| "The use of the furosemide stress test (FST) as an acute kidney injury (AKI) severity marker has been described in several trials." | 5.05 | Furosemide stress test as a predictive marker of acute kidney injury progression or renal replacement therapy: a systemic review and meta-analysis. ( Chang, CH; Chen, JJ; Huang, YT; Kuo, G, 2020) |
| "Our objective was to characterize cases of hospitalized heart failure (HHF) focusing on in-hospital resource utilization (particularly furosemide doses) and worsening heart failure (WHF), and identify which factors are associated with the length of stay (LOS)." | 3.96 | In-hospital resource utilization, worsening heart failure, and factors associated with length of hospital stay in patients with hospitalized heart failure: A Japanese database cohort study. ( Funakubo, M; Ishii, T; Matsui, N; Mitani, H; Murayama, H; Oyama, N; Rached, RA; Sato, N; Yoshida, S, 2020) |
| " This study aimed to compare the effect of torasemide and furosemide on long-term outcomes and New York Heart Association (NYHA) class change in patients with chronic heart failure (HF)." | 3.91 | Comparative Analysis of Long-Term Outcomes of Torasemide and Furosemide in Heart Failure Patients in Heart Failure Registries of the European Society of Cardiology. ( Balsam, P; Crespo-Leiro, MG; Drożdż, J; Filipiak, KJ; Grabowski, M; Kapłon-Cieślicka, A; Kowalik, R; Maggioni, AP; Marchel, M; Opolski, G; Ozierański, K; Peller, M; Tymińska, A; Wancerz, A, 2019) |
| "To validate the furosemide stress test (FST) for predicting the progression of acute kidney injury (AKI)." | 3.91 | The furosemide stress test for prediction of worsening acute kidney injury in critically ill patients: A multicenter, prospective, observational study. ( Bagshaw, SM; Chawla, LS; Koyner, JL; Liu, KD; McMahon, B; Rewa, OG; Shapiro, J; Smith, O; Trevino, SA; Wald, R; Wang, X, 2019) |
| "A long-acting loop diuretic, azosemide, has been shown to improve long-term prognosis in patients with heart failure compared with a short-acting loop diuretic, furosemide." | 3.91 | Patients With CONgestive Heart Failure Benefit From Long-Term Treatment Effects With Novel Treatment Using Azosemide Compared With Furosemide Derived From Existing Retrospective Study Data: CONTENTED. ( Abe, S; Arikawa, T; Inami, S; Inoue, T; Kanaya, T; Nishikawa, R; Saito, F; Sakuma, M; Toyoda, S; Watanabe, R, 2019) |
| "ECochG and glycerol and furosemide tests were performed in 1569 patients with various cochleovestibular diseases, including definite MD, atypical MD, syphilitic labyrinthitis, delayed endolymphatic hydrops, sudden hearing loss, cochleovestibulopathy and sensorineural hearing loss." | 3.72 | Prediction of progression from atypical to definite Ménière's disease using electrocochleography and glycerol and furosemide tests. ( Aso, S; Kimura, H; Watanabe, Y, 2003) |
| "Furosemide shortened the time to left ventricular dysfunction (35." | 3.72 | Furosemide and the progression of left ventricular dysfunction in experimental heart failure. ( Haigney, MC; Hanlon, SU; McCurley, JM; Michalski, M; Wedam, EF; Wei, SK, 2004) |
| "Forty patients with an AECOPD and high plasma BNP levels, but without any clinical evidence of cor pulmonale, were selected." | 2.77 | Intravenous diuretic and vasodilator therapy reduce plasma brain natriuretic peptide levels in acute exacerbation of chronic obstructive pulmonary disease. ( Pan, X; Yu, X; Zhang, J; Zhao, G, 2012) |
| "The cardiorenal syndrome is not well understood, and a uniform definition is lacking." | 2.43 | Acute decompensated heart failure: the cardiorenal syndrome. ( Francis, G, 2006) |
| "Coexistent hepatocellular carcinoma (HCC) was the only significant predictive variable that attenuated the efficacy of TLV." | 1.46 | Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma. ( Goya, T; Kato, M; Kohjima, M; Kotoh, K; Masumoto, A; Miyazaki, M; Motomura, K; Senjyu, T; Tanaka, K; Yada, M, 2017) |
| "Progression of tricuspid regurgitation (TR) may occur after mitral valve replacement (MVR)." | 1.46 | Progression of Tricuspid Regurgitation after Mitral Valve Replacement for Rheumatic Heart Disease. ( Q Tri, HH; Vinh, PN, 2017) |
| "Nitrates were given most often in pulmonary oedema and hypertensive AHF." | 1.39 | Management of acute heart failure and the effect of systolic blood pressure on the use of intravenous therapies. ( Harjola, VP; Lassus, J; Nieminen, MS; Siirilä-Waris, K; Tarvasmäki, T; Tolonen, J, 2013) |
| "We identified 423 patients with severe sepsis and electronically recorded continuous hemodynamic data in the prospective observational FINNAKI study." | 1.39 | Hemodynamic variables and progression of acute kidney injury in critically ill patients with severe sepsis: data from the prospective observational FINNAKI study. ( Hautamäki, R; Hovilehto, S; Inkinen, O; Karlsson, S; Kaukonen, KM; Korhonen, AM; Kuitunen, A; Laru-Sompa, R; Pettilä, V; Poukkanen, M; Uusaro, A; Vaara, ST; Wilkman, E, 2013) |
| "Since its introduction in cardiac failure in 1994, biventricular cardiac stimulation has been widely applied with many clinical trials and the development of new specific technology." | 1.31 | [Medium-term results of multisite biventricular stimulation in severe cardiac failure]. ( Alonso, C; Boulmier, D; Carré, F; Daubert, JC; de Place, C; Leclercq, C; Mabo, P; Pavin, D; Revault, dF, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (4.88) | 18.2507 |
| 2000's | 7 (17.07) | 29.6817 |
| 2010's | 28 (68.29) | 24.3611 |
| 2020's | 4 (9.76) | 2.80 |
| Authors | Studies |
|---|---|
| Rivero, J | 1 |
| Rodríguez, F | 1 |
| Soto, V | 1 |
| Macedo, E | 1 |
| Chawla, LS | 3 |
| Mehta, RL | 1 |
| Vaingankar, S | 1 |
| Garimella, PS | 1 |
| Garza, C | 1 |
| Madero, M | 1 |
| Chen, JJ | 1 |
| Chang, CH | 1 |
| Huang, YT | 1 |
| Kuo, G | 1 |
| Mitani, H | 1 |
| Funakubo, M | 1 |
| Sato, N | 1 |
| Murayama, H | 1 |
| Rached, RA | 1 |
| Matsui, N | 1 |
| Yoshida, S | 1 |
| Ishii, T | 1 |
| Oyama, N | 1 |
| Simonavičius, J | 1 |
| Maeder, MT | 1 |
| Eurlings, CGMJ | 1 |
| Aizpurua, AB | 1 |
| Čelutkienė, J | 1 |
| Barysienė, J | 1 |
| Toggweiler, S | 1 |
| Kaufmann, BA | 1 |
| Brunner-La Rocca, HP | 1 |
| Lee, G | 1 |
| Pickstone, N | 1 |
| Facultad, J | 1 |
| Titchener, K | 1 |
| Miyazaki, M | 1 |
| Yada, M | 1 |
| Tanaka, K | 1 |
| Senjyu, T | 1 |
| Goya, T | 1 |
| Motomura, K | 1 |
| Kohjima, M | 1 |
| Kato, M | 1 |
| Masumoto, A | 1 |
| Kotoh, K | 1 |
| Q Tri, HH | 1 |
| Vinh, PN | 1 |
| Ferreira, JP | 2 |
| Metra, M | 3 |
| Mordi, I | 1 |
| Gregson, J | 1 |
| Ter Maaten, JM | 3 |
| Tromp, J | 1 |
| Anker, SD | 2 |
| Dickstein, K | 2 |
| Hillege, HL | 2 |
| Ng, LL | 1 |
| van Veldhuisen, DJ | 2 |
| Lang, CC | 2 |
| Voors, AA | 4 |
| Zannad, F | 2 |
| Ozierański, K | 1 |
| Balsam, P | 1 |
| Kapłon-Cieślicka, A | 1 |
| Tymińska, A | 1 |
| Kowalik, R | 1 |
| Grabowski, M | 1 |
| Peller, M | 1 |
| Wancerz, A | 1 |
| Marchel, M | 1 |
| Crespo-Leiro, MG | 1 |
| Maggioni, AP | 1 |
| Drożdż, J | 1 |
| Filipiak, KJ | 1 |
| Opolski, G | 1 |
| Prasad, PV | 1 |
| Li, LP | 1 |
| Thacker, JM | 1 |
| Li, W | 1 |
| Hack, B | 1 |
| Kohn, O | 1 |
| Sprague, SM | 1 |
| Rewa, OG | 1 |
| Bagshaw, SM | 2 |
| Wang, X | 1 |
| Wald, R | 1 |
| Smith, O | 1 |
| Shapiro, J | 1 |
| McMahon, B | 1 |
| Liu, KD | 1 |
| Trevino, SA | 2 |
| Koyner, JL | 2 |
| Toyoda, S | 1 |
| Arikawa, T | 1 |
| Inami, S | 1 |
| Nishikawa, R | 1 |
| Saito, F | 1 |
| Watanabe, R | 1 |
| Sakuma, M | 1 |
| Kanaya, T | 1 |
| Abe, S | 1 |
| Inoue, T | 1 |
| Santos, M | 1 |
| Almeida, S | 1 |
| Marques, I | 1 |
| Bettencourt, P | 1 |
| Carvalho, H | 1 |
| Tarvasmäki, T | 1 |
| Harjola, VP | 1 |
| Tolonen, J | 1 |
| Siirilä-Waris, K | 1 |
| Nieminen, MS | 1 |
| Lassus, J | 1 |
| Poukkanen, M | 1 |
| Wilkman, E | 1 |
| Vaara, ST | 1 |
| Pettilä, V | 1 |
| Kaukonen, KM | 1 |
| Korhonen, AM | 1 |
| Uusaro, A | 1 |
| Hovilehto, S | 1 |
| Inkinen, O | 1 |
| Laru-Sompa, R | 1 |
| Hautamäki, R | 1 |
| Kuitunen, A | 1 |
| Karlsson, S | 1 |
| Rea, G | 1 |
| Valente, T | 1 |
| de Rosa, N | 1 |
| Muto, M | 1 |
| Berritto, D | 1 |
| Bocchino, M | 1 |
| Davison, DL | 1 |
| Brasha-Mitchell, E | 1 |
| Chalikonda, DM | 1 |
| Arthur, JM | 1 |
| Shaw, AD | 1 |
| Tumlin, JA | 1 |
| Bennett, MR | 1 |
| Kimmel, PL | 1 |
| Seneff, MG | 1 |
| Dunning, AM | 1 |
| Valente, MA | 1 |
| Damman, K | 1 |
| Ezekowitz, JA | 1 |
| Califf, RM | 1 |
| Starling, RC | 1 |
| van der Meer, P | 1 |
| O'Connor, CM | 2 |
| Schulte, PJ | 1 |
| Testani, JM | 2 |
| Hernandez, AF | 1 |
| Tang, WH | 2 |
| Mentz, RJ | 1 |
| Velazquez, EJ | 1 |
| McKendry, C | 1 |
| Chiswell, K | 1 |
| Fiuzat, M | 1 |
| Givertz, MM | 1 |
| Teerlink, JR | 1 |
| AlFaleh, H | 1 |
| Elasfar, AA | 1 |
| Ullah, A | 1 |
| AlHabib, KF | 1 |
| Hersi, A | 1 |
| Mimish, L | 1 |
| Almasood, A | 1 |
| Al Ghamdi, S | 1 |
| Ghabashi, A | 1 |
| Malik, A | 1 |
| Hussein, GA | 1 |
| Al-Murayeh, M | 1 |
| Abuosa, A | 1 |
| Al Habeeb, W | 1 |
| Kashour, T | 1 |
| Cleland, JG | 1 |
| Filippatos, G | 1 |
| van der Harst, P | 1 |
| Ng, L | 1 |
| Ponikowski, P | 1 |
| Samani, NJ | 1 |
| Zwinderman, AH | 1 |
| Brisco, MA | 1 |
| Zile, MR | 1 |
| Hanberg, JS | 1 |
| Wilson, FP | 1 |
| Parikh, CR | 1 |
| Coca, SG | 1 |
| Hou, W | 1 |
| Sanyal, AJ | 1 |
| Gibney, RT | 1 |
| McAlister, FA | 1 |
| Bellomo, R | 1 |
| Sipos, W | 1 |
| Hirschberger, J | 1 |
| Breuer, W | 1 |
| Zenker, I | 1 |
| Elicker, S | 1 |
| Rahman, M | 1 |
| Kim, SJ | 1 |
| Kim, JS | 1 |
| Kim, SZ | 1 |
| Lee, YU | 1 |
| Kang, HS | 1 |
| Rocha Araújo, FD | 1 |
| Brandão, KN | 1 |
| Araújo, FA | 1 |
| Vasconcelos Severiano, GM | 1 |
| Alves Meira, ZM | 1 |
| Parrinello, G | 1 |
| Torres, D | 1 |
| Paterna, S | 1 |
| Licata, G | 1 |
| Di Pasquale, P | 1 |
| Heras, M | 1 |
| Saiz, A | 1 |
| Pardo, J | 1 |
| Fernández-Reyes, MJ | 1 |
| Sánchez, R | 1 |
| Alvarez-Ude, F | 1 |
| Costello-Boerrigter, LC | 1 |
| Burnett, JC | 1 |
| Zhang, J | 1 |
| Zhao, G | 1 |
| Yu, X | 1 |
| Pan, X | 1 |
| Banerjee, P | 1 |
| Tanner, G | 1 |
| Williams, L | 1 |
| Koslow, M | 1 |
| Raskin, S | 1 |
| Sidi, Y | 1 |
| Ben-Dov, I | 1 |
| Segel, MJ | 1 |
| Kimura, H | 1 |
| Aso, S | 1 |
| Watanabe, Y | 1 |
| Dervaux, T | 1 |
| Moulin, B | 1 |
| McCurley, JM | 1 |
| Hanlon, SU | 1 |
| Wei, SK | 1 |
| Wedam, EF | 1 |
| Michalski, M | 1 |
| Haigney, MC | 1 |
| Francis, G | 1 |
| Nigro, G | 2 |
| Politano, L | 1 |
| Passamano, L | 1 |
| Palladino, A | 1 |
| De Luca, F | 1 |
| Comi, LI | 1 |
| Koller-Strametz, J | 1 |
| Pacher, R | 1 |
| Frey, B | 1 |
| Kos, T | 1 |
| Woloszczuk, W | 1 |
| Stanek, B | 1 |
| Ettinger, SJ | 1 |
| Benitz, AM | 1 |
| Ericsson, GF | 1 |
| Cifelli, S | 1 |
| Jernigan, AD | 1 |
| Longhofer, SL | 1 |
| Trimboli, W | 1 |
| Hanson, PD | 1 |
| Leclercq, C | 1 |
| Alonso, C | 1 |
| Revault, dF | 1 |
| Boulmier, D | 1 |
| de Place, C | 1 |
| Carré, F | 1 |
| Pavin, D | 1 |
| Mabo, P | 1 |
| Daubert, JC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Furosemide Stress Test as a Predictor of Tubular Atrophy and Interstitial Fibrosis in Patients With Chronic Kidney Disease[NCT02417883] | Phase 3 | 100 participants (Anticipated) | Interventional | 2015-04-30 | Recruiting | ||
| Outgoing Lung Team - a Cross-sectorial and Preventive Intervention in Patients at Risk of Hospitalisation Due to Exacerbation of COPD[NCT04119856] | 144 participants (Actual) | Interventional | 2017-09-25 | Completed | |||
| A Randomized, Open-label Study of Dapagliflozin in Patients With or Without Type 2 Diabetes Admitted With Acute Heart Failure[NCT04298229] | Phase 3 | 240 participants (Actual) | Interventional | 2020-04-01 | Completed | ||
| Continuous Versus Bolus Intermittent Loop Diuretic Infusion in Acutely Decompensated Heart Failure: Evaluation of Renal Function, Congestion Signs, BNP and Outcome[NCT02638142] | 116 participants (Actual) | Observational | 2015-12-31 | Active, not recruiting | |||
| "Early and Late Timing Indication for Starting Renal Replacement Therapy in Acute Renal Failure After Cardiac Surgery: a Prospective, Controlled, Interventional, Single-center Trial"[NCT01961999] | 1,800 participants (Actual) | Interventional | 2011-07-31 | Completed | |||
| A Phase II Randomized Blinded Controlled Trial of the Effect of furoSemide in Critically Ill Patients With eARly Acute Kidney Injury (The SPARK Study)[NCT00978354] | Phase 2/Phase 3 | 72 participants (Actual) | Interventional | 2009-09-30 | Terminated (stopped due to Feasibility of target enrollment within the context of available funding resources.) | ||
| Phase III Study of Furosemide Continuous Infusion Versus Ethacrynic Acid Continuous Infusion in Children Undergoing Cardiac Surgery: Randomized Double Blind Controlled Clinical Trial[NCT01628731] | Phase 3 | 74 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for furosemide and Disease Exacerbation
| Article | Year |
|---|---|
Furosemide stress test as a predictive marker of acute kidney injury progression or renal replacement therapy: a systemic review and meta-analysis.
Topics: Acute Kidney Injury; Disease Progression; Exercise Test; Furosemide; Humans; Predictive Value of Tes | 2020 |
Ascites: diagnosis and management.
Topics: Ascites; Ascitic Fluid; Cardiac Output; Diet, Sodium-Restricted; Disease Progression; Diuretics; Dru | 2009 |
[Modes of clinical presentation of glomerular diseases].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bed Rest; Biopsy; Child; D | 2003 |
Acute decompensated heart failure: the cardiorenal syndrome.
Topics: Acute Disease; Disease Progression; Diuretics; Furosemide; Glomerular Filtration Rate; Heart Failure | 2006 |
9 trials available for furosemide and Disease Exacerbation
| Article | Year |
|---|---|
Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Chronic Disease; Disease Progression; Diuretics; Edema; Fema | 2014 |
Furosemide Stress Test and Biomarkers for the Prediction of AKI Severity.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Aged; Albuminuria; Biomarkers; Creatinine; Disease Progre | 2015 |
Diuretic response in acute heart failure-an analysis from ASCEND-HF.
Topics: Acute Disease; Aged; Disease Progression; Diuretics; Dose-Response Relationship, Drug; Double-Blind | 2015 |
Diuretic response in acute heart failure-an analysis from ASCEND-HF.
Topics: Acute Disease; Aged; Disease Progression; Diuretics; Dose-Response Relationship, Drug; Double-Blind | 2015 |
Diuretic response in acute heart failure-an analysis from ASCEND-HF.
Topics: Acute Disease; Aged; Disease Progression; Diuretics; Dose-Response Relationship, Drug; Double-Blind | 2015 |
Diuretic response in acute heart failure-an analysis from ASCEND-HF.
Topics: Acute Disease; Aged; Disease Progression; Diuretics; Dose-Response Relationship, Drug; Double-Blind | 2015 |
Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial.
Topics: Aged; Disease Progression; Diuretics; Dose-Response Relationship, Drug; Europe; Female; Follow-Up St | 2015 |
Relevance of Changes in Serum Creatinine During a Heart Failure Trial of Decongestive Strategies: Insights From the DOSE Trial.
Topics: Aged; Biomarkers; Cause of Death; Creatinine; Disease Progression; Disease-Free Survival; Diuretics; | 2016 |
The SPARK Study: a phase II randomized blinded controlled trial of the effect of furosemide in critically ill patients with early acute kidney injury.
Topics: Acute Disease; Adult; Alberta; Biomarkers; Critical Illness; Disease Progression; Diuretics; Female; | 2010 |
The SPARK Study: a phase II randomized blinded controlled trial of the effect of furosemide in critically ill patients with early acute kidney injury.
Topics: Acute Disease; Adult; Alberta; Biomarkers; Critical Illness; Disease Progression; Diuretics; Female; | 2010 |
The SPARK Study: a phase II randomized blinded controlled trial of the effect of furosemide in critically ill patients with early acute kidney injury.
Topics: Acute Disease; Adult; Alberta; Biomarkers; Critical Illness; Disease Progression; Diuretics; Female; | 2010 |
The SPARK Study: a phase II randomized blinded controlled trial of the effect of furosemide in critically ill patients with early acute kidney injury.
Topics: Acute Disease; Adult; Alberta; Biomarkers; Critical Illness; Disease Progression; Diuretics; Female; | 2010 |
The SPARK Study: a phase II randomized blinded controlled trial of the effect of furosemide in critically ill patients with early acute kidney injury.
Topics: Acute Disease; Adult; Alberta; Biomarkers; Critical Illness; Disease Progression; Diuretics; Female; | 2010 |
The SPARK Study: a phase II randomized blinded controlled trial of the effect of furosemide in critically ill patients with early acute kidney injury.
Topics: Acute Disease; Adult; Alberta; Biomarkers; Critical Illness; Disease Progression; Diuretics; Female; | 2010 |
The SPARK Study: a phase II randomized blinded controlled trial of the effect of furosemide in critically ill patients with early acute kidney injury.
Topics: Acute Disease; Adult; Alberta; Biomarkers; Critical Illness; Disease Progression; Diuretics; Female; | 2010 |
The SPARK Study: a phase II randomized blinded controlled trial of the effect of furosemide in critically ill patients with early acute kidney injury.
Topics: Acute Disease; Adult; Alberta; Biomarkers; Critical Illness; Disease Progression; Diuretics; Female; | 2010 |
The SPARK Study: a phase II randomized blinded controlled trial of the effect of furosemide in critically ill patients with early acute kidney injury.
Topics: Acute Disease; Adult; Alberta; Biomarkers; Critical Illness; Disease Progression; Diuretics; Female; | 2010 |
Myocardial calcification and hypertension following chronic renal failure and ameliorative effects of furosemide and captopril.
Topics: Analysis of Variance; Animals; Antihypertensive Agents; Calcinosis; Captopril; Cardiomyopathies; Dis | 2010 |
Intravenous diuretic and vasodilator therapy reduce plasma brain natriuretic peptide levels in acute exacerbation of chronic obstructive pulmonary disease.
Topics: Aged; Aminophylline; Bronchodilator Agents; Disease Progression; Drug Combinations; Female; Furosemi | 2012 |
Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. The Long-Term Investigation of Veterinary Enalapril (LIVE) Study Group.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomyopathy, Dilated; Cardiotonic Agents; Deat | 1998 |
28 other studies available for furosemide and Disease Exacerbation
| Article | Year |
|---|---|
Furosemide stress test and interstitial fibrosis in kidney biopsies in chronic kidney disease.
Topics: Adult; Biopsy; Disease Progression; Female; Fibrosis; Furosemide; Humans; Kidney; Kidney Tubules, Pr | 2020 |
In-hospital resource utilization, worsening heart failure, and factors associated with length of hospital stay in patients with hospitalized heart failure: A Japanese database cohort study.
Topics: Aged; Aged, 80 and over; Cohort Studies; Databases, Factual; Disease Progression; Female; Furosemide | 2020 |
Intensification of pharmacological decongestion but not the actual daily loop diuretic dose predicts worse chronic heart failure outcome: insights from TIME-CHF.
Topics: Aged; Aged, 80 and over; Chronic Disease; Disease Progression; Female; Furosemide; Germany; Heart Fa | 2021 |
The future of community nursing: Hospital in the Home.
Topics: Acute Disease; Aged; Anti-Bacterial Agents; Bronchodilator Agents; Clergy; Community Health Nursing; | 2017 |
Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Body Weig | 2017 |
Progression of Tricuspid Regurgitation after Mitral Valve Replacement for Rheumatic Heart Disease.
Topics: Adult; Chi-Square Distribution; Disease Progression; Echocardiography, Doppler; Female; Furosemide; | 2017 |
Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study.
Topics: Aged; Disease Progression; Diuretics; Europe; Female; Furosemide; Heart Failure; Hospitalization; Hu | 2019 |
Comparative Analysis of Long-Term Outcomes of Torasemide and Furosemide in Heart Failure Patients in Heart Failure Registries of the European Society of Cardiology.
Topics: Aged; Disease Progression; Female; Furosemide; Heart Failure; Humans; Male; Middle Aged; Poland; Rec | 2019 |
Cortical Perfusion and Tubular Function as Evaluated by Magnetic Resonance Imaging Correlates with Annual Loss in Renal Function in Moderate Chronic Kidney Disease.
Topics: Aged; Cell Hypoxia; Diffusion Magnetic Resonance Imaging; Disease Progression; Female; Furosemide; G | 2019 |
The furosemide stress test for prediction of worsening acute kidney injury in critically ill patients: A multicenter, prospective, observational study.
Topics: Acute Kidney Injury; Aged; Area Under Curve; Critical Illness; Disease Progression; Female; Furosemi | 2019 |
Patients With CONgestive Heart Failure Benefit From Long-Term Treatment Effects With Novel Treatment Using Azosemide Compared With Furosemide Derived From Existing Retrospective Study Data: CONTENTED.
Topics: Aged; Aged, 80 and over; Disease Progression; Female; Furosemide; Glomerular Filtration Rate; Heart | 2019 |
Management of acute heart failure and the effect of systolic blood pressure on the use of intravenous therapies.
Topics: Acute Disease; Aged; Analgesics, Opioid; Blood Pressure; Cardiotonic Agents; Chronic Disease; Diseas | 2013 |
Hemodynamic variables and progression of acute kidney injury in critically ill patients with severe sepsis: data from the prospective observational FINNAKI study.
Topics: Acute Kidney Injury; Blood Pressure; Disease Progression; Dobutamine; Furosemide; Hemodynamics; Huma | 2013 |
Pulmonary capillary hemangiomatosis: a diagnostic challenge.
Topics: Carbazoles; Carvedilol; Delayed Diagnosis; Disease Progression; Furosemide; Granuloma, Pyogenic; Hum | 2015 |
Worsening heart failure in 'real-world' clinical practice: predictors and prognostic impact.
Topics: Acute Disease; Adrenergic beta-Antagonists; Cardiotonic Agents; Disease Progression; Diuretics; Drug | 2017 |
A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin- | 2016 |
Partial remission of mast cell leukaemia in a minipig after chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Drug | 2010 |
Cardiac tamponade as a rare form of presentation of rheumatic carditis.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Antihypertensive Agents; Captopril; Cardiac Tampona | 2010 |
Time to ferry heart failure onto new shores: the need to effectively customize long-term therapy.
Topics: Disease Progression; Diuretics; Furosemide; Heart Failure; Humans; Treatment Outcome | 2011 |
[Rapidly progressive renal failure as the onset of an IgA nephropathy in an elderly patient].
Topics: Acute Kidney Injury; Adenocarcinoma; Aged; Biphenyl Compounds; Disease Progression; Diuretics; Doxaz | 2011 |
Heart failure: furosemide--to DOSE or not to DOSE, that is the question.
Topics: Biomarkers; Disease Progression; Diuretics; Furosemide; Heart Failure; Humans | 2011 |
Intravenous diuretic day-care treatment for patients with heart failure.
Topics: Aged; Aged, 80 and over; Cost Savings; Day Care, Medical; Disease Management; Disease Progression; D | 2012 |
An 82-year-old woman with progressive dyspnea and bilateral infiltrates.
Topics: Aged, 80 and over; Disease Progression; Diuretics; Dyspnea; Female; Furosemide; Heart Failure; Human | 2013 |
Prediction of progression from atypical to definite Ménière's disease using electrocochleography and glycerol and furosemide tests.
Topics: Adolescent; Adult; Aged; Audiometry, Evoked Response; Child; Cochlear Diseases; Disease Progression; | 2003 |
Furosemide and the progression of left ventricular dysfunction in experimental heart failure.
Topics: Adrenergic beta-Agonists; Aldosterone; Animals; Biomarkers; Disease Models, Animal; Disease Progress | 2004 |
Cardiac treatment in neuro-muscular diseases.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Cardiac Output, Low; Case-Contro | 2006 |
Circulating tumor necrosis factor-alpha levels in chronic heart failure: relation to its soluble receptor II, interleukin-6, and neurohumoral variables.
Topics: Adrenergic Agonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiotonic | 1998 |
[Medium-term results of multisite biventricular stimulation in severe cardiac failure].
Topics: Aged; Aged, 80 and over; Cardiac Pacing, Artificial; Disease Progression; Diuretics; Female; Follow- | 2002 |